U.S. Stock News

NasdaqGS:ALRM
NasdaqGS:ALRMSoftware

Why Alarm.com (ALRM) Is Up 5.8% After Raising Guidance And Unveiling AI-Powered SaaS Push

In early May 2026, Alarm.com Holdings reported first-quarter revenue of US$265.19 million, up from US$238.82 million a year earlier, while GAAP net income eased to US$23.58 million and diluted earnings per share from continuing operations moved to US$0.47 from US$0.52. Alongside raising its full-year 2026 outlook, the company highlighted double-digit SaaS and license revenue growth, new AI-driven video analytics features, and a US$150 million share repurchase authorization, underscoring...
NYSE:DLB
NYSE:DLBSoftware

Is Dolby (DLB) Using Buybacks And Dividends To Quietly Redefine Its Premium Audio Strategy?

Dolby Laboratories, Inc. recently reported its second-quarter fiscal 2026 results, with revenue of US$395.63 million and net income of US$94.92 million, and issued third-quarter and full-year 2026 guidance alongside confirming a quarterly dividend of US$0.36 per share and progress on its long-running share repurchase program. An interesting detail is that since the buyback’s initiation in 2009, Dolby has retired over 54.33 million shares for about US$3.16 billion, materially shrinking its...
NYSE:BA
NYSE:BAAerospace & Defense

Is Boeing (BA) Offering Value After Safety Concerns And A Mixed Valuation Picture?

If you are wondering whether Boeing's current share price gives you good value, it helps to separate headline noise from what the numbers actually suggest about the stock. Boeing's stock most recently closed at US$231.03, with total returns of 0.9% over 7 days, 10.0% over 30 days, 1.4% year to date, 20.5% over 1 year, 14.5% over 3 years and 3.8% over 5 years. Recent attention on Boeing has focused on safety and quality issues across parts of its commercial aircraft business, with regulatory...
NasdaqCM:DNTH
NasdaqCM:DNTHBiotechs

Should Dianthus Therapeutics’ (DNTH) Big Cash Raise and LBL-047 Bet Prompt Investor Reassessment?

Nanjing Leads Biolabs Co. Ltd. recently announced that partner Dianthus Therapeutics selected Sjögren's disease, systemic lupus erythematosus, and dermatomyositis as priority indications for LBL-047, while Dianthus also reported a wider first-quarter 2026 net loss of US$40.83 million alongside an upsized public offering that raised about US$719 million. The decision to advance LBL-047, a bifunctional fusion protein targeting both pDC-driven Type 1 interferon and BAFF/APRIL B‑cell pathways,...
NasdaqGS:GRAB
NasdaqGS:GRABTransportation

Assessing Grab Holdings (GRAB) Valuation After Strong Q1 Earnings And AI Growth Updates

Why Grab’s Q1 earnings matter for shareholders Grab Holdings (GRAB) reported first quarter 2026 revenue of US$955 million and net income of US$136 million, both higher than a year earlier, with earnings surpassing analyst expectations and indicating improved operational efficiency. See our latest analysis for Grab Holdings. The Q1 beat and updates on AI products, autonomous rides and financial services come against a mixed share price backdrop, with a 6.5% 1 month share price return but a...
NYSE:RKT
NYSE:RKTDiversified Financial

AI-Fueled Turnaround and Recurring Revenue Shift Could Be A Game Changer For Rocket Companies (RKT)

Rocket Companies, Inc. reported past first-quarter 2026 results with revenue rising to US$2.94 billion from US$1.10 billion a year earlier, swinging from a US$10 million net loss to US$297 million in net income and returning to positive earnings per share. Management linked this performance to over US$500 million of AI investment, faster-than-planned integration of Mr. Cooper and Redfin, and a shift toward recurring or less rate-sensitive revenue streams that now account for roughly 70% of...
NasdaqGS:NWL
NasdaqGS:NWLConsumer Durables

Assessing Newell Brands (NWL) Valuation After The Toy Story 5 Collaboration With Disney And Pixar

Newell Brands (NWL) is drawing fresh attention after unveiling a Toy Story 5 themed Sharpie and Elmer’s collection with Disney and Pixar, a marketing driven collaboration that could influence how investors view the stock. See our latest analysis for Newell Brands. The Toy Story 5 collaboration lands after a volatile stretch, with a 30 day share price return of 25% and a year to date share price gain of 19.62%. This is set against a 1 year total shareholder return decline of 10.18%, which...
NasdaqGS:SYNA
NasdaqGS:SYNASemiconductor

Synaptics (SYNA) Is Up 13.0% After Core IoT-Fueled Q3 Beat And Google AI Partnership Unveiled

Synaptics recently reported third-quarter fiscal 2026 results, with revenue rising to US$294.2 million from US$266.6 million a year earlier, while its net loss narrowed to US$8.0 million from US$21.8 million. Beneath the headline numbers, management emphasized rapidly growing Core IoT sales, expanding Physical AI and Edge AI design wins, and a deepening collaboration with Google on next-generation AI hardware platforms. Next, we’ll explore how the strong Core IoT growth and Physical AI...
NYSE:STC
NYSE:STCInsurance

A Look At Stewart Information Services (STC) Valuation As Mixed Signals Emerge On Growth And P/E Ratios

Key recent performance and business mix Stewart Information Services (STC) has seen mixed share price moves recently, with a gain over the past month alongside a small decline over the past 3 months and year to date. The stock’s past year total return of 11.5% contrasts with a modest loss over the past 3 years. Over 5 years, the total return stands at 35.96%, giving investors a varied performance profile to assess. On the fundamentals side, the company reports annual revenue of US$3.10b and...
NasdaqGS:ROP
NasdaqGS:ROPSoftware

What Roper Technologies (ROP)'s AI-Fueled Outlook Hike and New Credit Line Means For Shareholders

In the past quarter, Roper Technologies reported Q1 2026 adjusted DEPS of US$5.16, 11.3% revenue growth, raised its full-year profit outlook, and arranged a US$3.50 billion revolving credit facility to support future acquisitions. A key takeaway is that AI-driven demand across Roper’s software portfolio is becoming a central earnings driver while the larger credit line enhances financial flexibility for further portfolio expansion. We’ll now examine how Roper’s raised profit outlook,...
NasdaqGS:ACAD
NasdaqGS:ACADBiotechs

A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback

ACADIA Pharmaceuticals (ACAD) is back in focus after first quarter 2026 results showed 10% year over year revenue growth to US$268.1 million, alongside weaker earnings, higher expenses, and a setback for trofinetide in Europe. See our latest analysis for ACADIA Pharmaceuticals. The mixed Q1 2026 update, together with the negative EU opinion on trofinetide and leadership changes in research and development, appears to be feeding into a share price that has struggled year to date despite a...
NasdaqGS:XERS
NasdaqGS:XERSPharmaceuticals

A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Profit Turnaround And Guidance Hike

Xeris Biopharma Holdings (XERS) stock is in focus after the company reported a profitable first quarter of 2026 and raised its full year revenue guidance to US$380 million to US$390 million. See our latest analysis for Xeris Biopharma Holdings. The guidance hike and first quarter profit have come after a mixed period for the stock, with a 12.95% 1 month share price return and a 9.80% year to date share price decline. At the same time, 1 year and 3 year total shareholder returns of 28.49% and...
NasdaqGM:IESC
NasdaqGM:IESCConstruction

Is IES Holdings (IESC) Still Fairly Valued After Strong Q2 Earnings And Share Price Surge

IES Holdings (IESC) shares have been moving after the company reported second quarter 2026 earnings, with higher sales, net income, and earnings per share compared with the same period a year earlier. See our latest analysis for IES Holdings. The earnings release and the recent agreement to acquire Broadwind's Abilene facility have come alongside strong share price momentum, with a 30 day share price return of 38.13% and a 1 year total shareholder return of 165.60%. Multi year total...
NasdaqGS:SHC
NasdaqGS:SHCLife Sciences

A Look At Sotera Health (SHC) Valuation After Q1 2026 Results And CEO Transition

Sotera Health (SHC) just delivered a busy first quarter, pairing 10% year-over-year revenue growth and a move back to profitability with reaffirmed 2026 guidance and a planned CEO transition. See our latest analysis for Sotera Health. The share price is US$15.67 after a 7.04% 1 month share price return. However, the 90 day share price return of 11.72% and year to date share price return of 11.42% suggest recent momentum has cooled. Even so, the 1 year total shareholder return of 18.44% and 3...
NYSE:PR
NYSE:PROil and Gas

Assessing Permian Resources (PR) Valuation After Strong Recent Returns And Higher P/E Multiple

Permian Resources (PR) is back in focus after recent share price moves, with the stock now around US$20.08. Investors are weighing its latest returns, revenue profile and intrinsic value signals. See our latest analysis for Permian Resources. While the share price has pulled back recently, with a 1-day share price return of 5.33% and a 7-day share price return of 7.12%, momentum over longer periods remains strong. This includes a 39.44% year to date share price return and a very strong 5-year...
NasdaqGS:TSLA
NasdaqGS:TSLAAuto

Tesla (TSLA) Is Up 7.9% After Record Semi Deal And AI Push - Has The Bull Case Changed?

In recent weeks, Tesla has reported a rebound in China-made EV sales, secured its largest-ever Semi truck order from WattEV worth about US$100 million, posted stronger quarterly earnings with margin recovery, and advanced major AI, robotaxi and chip initiatives including the Terafab semiconductor project in Texas. Taken together with the Model Y clearing new US safety evaluations and ongoing robotaxi pilots, these developments underscore Tesla’s push to reposition itself as a vertically...
NYSE:CRI
NYSE:CRILuxury

A Look At Carter's (CRI) Valuation After Its First Quarter Earnings Beat And Upgraded Guidance

Earnings beat and guidance reset the conversation for Carter's stock Carter's (CRI) stock is back in focus after first quarter 2026 results came in ahead of analyst expectations on both revenue and profit, along with Q2 and full year guidance that surprised positively. See our latest analysis for Carter's. At a share price of $35.75, Carter's has a year to date share price return of 7.68%, while the 1 year total shareholder return stands at 7.31%. This is set against a weaker 3 year and 5...
NasdaqGM:PAYO
NasdaqGM:PAYODiversified Financial

A Look At Payoneer Global (PAYO) Valuation After Recent Mixed Share Performance

Event context and recent share performance Payoneer Global (PAYO) has drawn attention after a period of mixed share performance, with the stock up about 4.1% over the past day and 5.2% over the past month, but showing a 20.1% decline over the past 3 months. See our latest analysis for Payoneer Global. That recent 1-day share price return of 4.1% and 30-day share price return of 5.2% sit against a weaker backdrop, with a 90-day share price return showing a 20.1% decline and a 1-year total...
NasdaqGS:DXCM
NasdaqGS:DXCMMedical Equipment

A Look At DexCom (DXCM) Valuation After Strong Q1 Growth And Upgraded Profitability Guidance

Why DexCom's latest earnings matter for investors DexCom (DXCM) just reported first quarter 2026 results, with revenue of US$1.192b and net income of US$199.5m, alongside higher margins and updated profitability guidance that put cash generation and product momentum in focus. See our latest analysis for DexCom. Despite the strong first quarter update and profitability guidance, DexCom's recent share price performance has been weak. The 90 day share price return shows a 12.95% decline and the...
NasdaqGS:NUVL
NasdaqGS:NUVLBiotechs

Assessing Nuvalent (NUVL) Valuation After NDA Milestones Guardant Alliance And Quarterly Loss

Nuvalent (NUVL) is in focus after a cluster of company updates, including first quarter earnings that showed a net loss of US$109.28 million and new detail on late stage oncology milestones. See our latest analysis for Nuvalent. At a share price of US$102.40, Nuvalent has seen mixed short term moves, with a 1 day share price return of 1.78% decline but a 1 year total shareholder return of 43.02%. This points to stronger momentum over a longer window as investors weigh the NDA progress,...
NasdaqGS:BEAM
NasdaqGS:BEAMBiotechs

Will Beam Therapeutics' (BEAM) Revenue Surge, Pipeline Updates and Added Liquidity Change Its Narrative?

In the first quarter of 2026, Beam Therapeutics reported a net loss of US$94.32 million (US$0.91 per share) alongside a very large year-over-year revenue increase to US$31.74 million, largely driven by collaboration milestones. At the same time, Beam advanced its base-editing pipeline with positive BEAM-302 and risto-cel data, outlined plans for a potential accelerated path to approval in multiple rare diseases, and reinforced its liquidity with US$1.20 billion in cash and a new US$100...
NYSE:MTN
NYSE:MTNHospitality

How Cheaper Fuel And Insider Equity Vesting At Vail Resorts (MTN) Has Changed Its Investment Story

Recently, Vail Resorts benefited from a sharp fall in crude oil prices tied to optimism about reopening the Strait of Hormuz, which could ease fuel-related cost pressures across the travel and leisure sector. An insider equity vesting by executive Julie A. DeCecco also occurred in early May, highlighting ongoing equity-based compensation alignment between management and shareholders. Next, we’ll examine how lower oil-related operating costs might influence Vail Resorts’ existing investment...
NYSE:LMND
NYSE:LMNDInsurance

A Look At Lemonade (LMND) Valuation As Renters Insurance Expands Into Two New States

Lemonade (LMND) has expanded its renters insurance into New Hampshire and West Virginia, extending its digital, app based coverage to more U.S. renters and putting the stock back on many investors’ radar. See our latest analysis for Lemonade. The renters expansion arrives after a busy few weeks, including first quarter results on 29 April that showed revenue of US$258 million and a net loss of US$35.8 million. This came alongside a 1 year total shareholder return of 74.34% contrasted with a...
NasdaqGS:ALGN
NasdaqGS:ALGNMedical Equipment

Assessing Align Technology (ALGN) Valuation After Q1 2026 Earnings Beat And Product Updates

Align Technology (ALGN) is back in focus after its Q1 2026 earnings release, reaffirmed guidance, and a fresh wave of clear aligner and digital workflow product updates previewed at the AAO 2026 orthodontics conference. See our latest analysis for Align Technology. Despite the Q1 2026 earnings beat, reaffirmed guidance, and product updates previewed around AAO 2026, the stock’s 1-day share price return of 3.19% decline and 7-day share price return of 4.33% decline suggest some near term...